Efficacy of glatiramer acetate in neuromyelitis optica spectrum disorder: a multicenter retrospective study

Journal of Neurology

Volumn 263, Issue 3, 2016, Pages 575-582

  Ayzenberg, Ilya ^a   Schöllhammer, Joanna ^a   Hoepner, Robert ^a   Hellwig, Kerstin ^a   Ringelstein, Marius ^b   Aktas, Orhan ^b   Kümpfel, Tania ^c   Krumbholz, Markus ^c,d   Trebst, Corinna ^e   Paul, Friedemann ^f,l   Pache, Florence ^f   Obermann, Mark ^g   Zeltner, Lena ^h   Schwab, Matthias ⁱ   Berthele, Achim ^j   Jarius, Sven ^k   Kleiter, Ingo ^a  

^a ST JOSEF HOSPITAL   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

^c UNIVERSITY OF MUNICH   (Germany)

^d UNIVERSITY OF TÜBINGEN   (Germany)

^e HANNOVER MEDICAL SCHOOL   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF DUISBURG ESSEN   (Germany)

^h UNIVERSITY OF TÜBINGEN   (Germany)

ⁱ JENA UNIVERSITY HOSPITAL   (Germany)

^j TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^k UNIVERSITY OF HEIDELBERG   (Germany)

^l MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

more..

Author keywords

Aquaporin 4 antibody; Devic s disease; Glatiramer acetate; Myelitis; Neuromyelitis optica spectrum disorder; Optic neuritis

Indexed keywords

AQUAPORIN 4 ANTIBODY; AZATHIOPRINE; BETA INTERFERON; GLATIRAMER; MITOXANTRONE; RITUXIMAB; TERIFLUNOMIDE; ANTIBODY; AQP4 PROTEIN, HUMAN; AQUAPORIN 4; IMMUNOSUPPRESSIVE AGENT;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG EFFICACY; DRUG WITHDRAWAL; EXPANDED DISABILITY STATUS SCALE; FEMALE; FOLLOW UP; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INJECTION SITE REACTION; LOCAL SKIN REACTION; MALE; MYELOOPTIC NEUROPATHY; NEUROMYELITIS OPTICA SPECTRUM DISORDER; PRIORITY JOURNAL; RECURRENCE RISK; RELAPSE; RETROSPECTIVE STUDY; TREATMENT RESPONSE; BLOOD; CLINICAL TRIAL; DISABILITY; IMMUNOLOGY; MIDDLE AGED; MULTICENTER STUDY; NEUROMYELITIS OPTICA; NONPARAMETRIC TEST; TREATMENT OUTCOME; YOUNG ADULT;

ADULT; ANTIBODIES; AQUAPORIN 4; DISABILITY EVALUATION; FEMALE; FOLLOW-UP STUDIES; GLATIRAMER ACETATE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; NEUROMYELITIS OPTICA; RETROSPECTIVE STUDIES; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84960372910     PISSN: 03405354     EISSN: 14321459     Source Type: Journal    
DOI: 10.1007/s00415-015-7991-1     Document Type: Article

References (34)

1. Jarius S, Wildemann B, Paul F (2014) Neuromyelitis optica: clinical features, immunopathogenesis and treatment. Clin Exp Immunol 176:149–164. doi:10.1111/cei.12271
2. Lennon VA, Wingerchuk DM, Kryzer TJ, Pittock SJ, Lucchinetti CF, Fujihara K, Nakashima I, Weinshenker BG (2004) A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 364:2106–2112. doi:10.1016/S0140-6736(04)17551-X
3. Wingerchuk DM, Banwell B, Bennett JL, Cabre P, Carroll W, Chitnis T, de Seze J, Fujihara K, Greenberg B, Jacob A, Jarius S, Lana-Peixoto M, Levy M, Simon JH, Tenembaum S, Traboulsee AL, Waters P, Wellik KE, Weinshenker BG (2015) International consensus diagnostic criteria for neuromyelitis optica spectrum disorders. Neurology 85:177–189. doi:10.1212/WNL.0000000000001729
4. Shimizu J, Hatanaka Y, Hasegawa M, Iwata A, Sugimoto I, Date H, Goto J, Shimizu T, Takatsu M, Sakurai Y, Nakase H, Uesaka Y, Hashida H, Hashimoto K, Komiya T, Tsuji S (2010) IFNβ-1b may severely exacerbate Japanese optic-spinal MS in neuromyelitis optica spectrum. Neurology 75:1423–1427. doi:10.1212/WNL.0b013e3181f8832e
5. Palace J, Leite MI, Nairne A, Vincent A (2010) Interferon Beta treatment in neuromyelitis optica: increase in relapses and aquaporin 4 antibody titers. Arch Neurol 67:1016–1017. doi:10.1001/archneurol.2010.188
6. Kleiter I, Hellwig K, Berthele A, Kümpfel T, Linker RA, Hartung H-P, Paul F, Aktas O, Neuromyelitis Optica Study Group (2012) Failure of natalizumab to prevent relapses in neuromyelitis optica. Arch Neurol 69:239–245. doi:10.1001/archneurol.2011.216
7. Kira J, Itoyama Y, Kikuchi S, Hao Q, Kurosawa T, Nagato K, Tsumiyama I, von Rosenstiel P, Zhang-Auberson L, Saida T (2014) Fingolimod (FTY720) therapy in Japanese patients with relapsing multiple sclerosis over 12 months: results of a phase 2 observational extension. BMC Neurol 14:21. doi:10.1186/1471-2377-14-21
8. Sellner J, Boggild M, Clanet M, Hintzen RQ, Illes Z, Montalban X, Du Pasquier RA, Polman CH, Sorensen PS, Hemmer B (2010) EFNS guidelines on diagnosis and management of neuromyelitis optica. Eur J Neurol Off J Eur Fed Neurol Soc 17:1019–1032. doi:10.1111/j.1468-1331.2010.03066.x
9. Trebst C, Jarius S, Berthele A, Paul F, Schippling S, Wildemann B, Borisow N, Kleiter I, Aktas O, Kümpfel T, Neuromyelitis Optica Study Group (NEMOS) (2014) Update on the diagnosis and treatment of neuromyelitis optica: recommendations of the Neuromyelitis Optica Study Group (NEMOS). J Neurol 261:1–16. doi:10.1007/s00415-013-7169-7
10. Ringelstein M, Ayzenberg I, Harmel J, Lauenstein A-S, Lensch E, Stögbauer F, Hellwig K, Ellrichmann G, Stettner M, Chan A, Hartung H-P, Kieseier B, Gold R, Aktas O, Kleiter I (2015) Long-term therapy with interleukin 6 receptor blockade in highly active neuromyelitis optica spectrum disorder. JAMA Neurol 72:756–763. doi:10.1001/jamaneurol.2015.0533
11. Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, Myers LW, Panitch HS, Rose JW, Schiffer RB (1995) Copolymer 1 reduces relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase III multicenter, double-blind placebo-controlled trial. The Copolymer 1 Multiple Sclerosis Study Group. Neurology 45:1268–1276
12. Wang K-C, Lee C-L, Chen S-Y, Lin K-H, Tsai C-P (2011) Glatiramer acetate could be a hypothetical therapeutic agent for neuromyelitis optica. Med Hypotheses 76:820–822. doi:10.1016/j.mehy.2011.02.027
13. Begum-Haque S, Sharma A, Christy M, Lentini T, Ochoa-Reparaz J, Fayed IF, Mielcarz D, Haque A, Kasper LH (2010) Increased expression of B cell-associated regulatory cytokines by glatiramer acetate in mice with experimental autoimmune encephalomyelitis. J Neuroimmunol 219:47–53. doi:10.1016/j.jneuroim.2009.11.016
14. Begum-Haque S, Sharma A, Kasper IR, Foureau DM, Mielcarz DW, Haque A, Kasper LH (2008) Downregulation of IL-17 and IL-6 in the central nervous system by glatiramer acetate in experimental autoimmune encephalomyelitis. J Neuroimmunol 204:58–65. doi:10.1016/j.jneuroim.2008.07.018
15. Jarius S, Ruprecht K, Wildemann B, Kuempfel T, Ringelstein M, Geis C, Kleiter I, Kleinschnitz C, Berthele A, Brettschneider J, Hellwig K, Hemmer B, Linker RA, Lauda F, Mayer CA, Tumani H, Melms A, Trebst C, Stangel M, Marziniak M, Hoffmann F, Schippling S, Faiss JH, Neuhaus O, Ettrich B, Zentner C, Guthke K, Hofstadt-van Oy U, Reuss R, Pellkofer H, Ziemann U, Kern P, Wandinger KP, Bergh FT, Boettcher T, Langel S, Liebetrau M, Rommer PS, Niehaus S, Münch C, Winkelmann A, Zettl UUK, Metz I, Veauthier C, Sieb JP, Wilke C, Hartung HP, Aktas O, Paul F (2012) Contrasting disease patterns in seropositive and seronegative neuromyelitis optica: a multicentre study of 175 patients. J Neuroinflammation 9:14. doi:10.1186/1742-2094-9-14
16. Bergamaschi R (2003) Glatiramer acetate treatment in Devic’s neuromyelitis optica. Brain J Neurol 126:1E (author reply 1E–a)
17. Gartzen K, Limmroth V, Putzki N (2007) Relapsing neuromyelitis optica responsive to glatiramer acetate treatment. Eur J Neurol Off J Eur Fed Neurol Soc 14:e12–e13. doi:10.1111/j.1468-1331.2007.01807.x
18. Jarius S, Aboul-Enein F, Waters P, Kuenz B, Hauser A, Berger T, Lang W, Reindl M, Vincent A, Kristoferitsch W (2008) Antibody to aquaporin-4 in the long-term course of neuromyelitis optica. Brain J Neurol 131:3072–3080. doi:10.1093/brain/awn240
19. Zamvil SS, Slavin AJ (2015) Does MOG Ig-positive AQP4-seronegative opticospinal inflammatory disease justify a diagnosis of NMO spectrum disorder? Neurol Neuroimmunol Neuroinflammation 2:e62. doi:10.1212/NXI.0000000000000062
20. Ireland SJ, Guzman AA, O’Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL (2014) The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis. JAMA Neurol 71:1421–1428. doi:10.1001/jamaneurol.2014.1472
21. Khatri BO, Kramer J, Dukic M, Palencia M, Verre W (2012) Maintenance plasma exchange therapy for steroid-refractory neuromyelitis optica. J Clin Apheresis 27:183–192. doi:10.1002/jca.21215
22. Araki M, Matsuoka T, Miyamoto K, Kusunoki S, Okamoto T, Murata M, Miyake S, Aranami T, Yamamura T (2014) Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study. Neurology 82:1302–1306. doi:10.1212/WNL.0000000000000317
23. Kitley J, Elsone L, George J, Waters P, Woodhall M, Vincent A, Jacob A, Leite MI, Palace J (2013) Methotrexate is an alternative to azathioprine in neuromyelitis optica spectrum disorders with aquaporin-4 antibodies. J Neurol Neurosurg Psychiatry 84:918–921. doi:10.1136/jnnp-2012-304774
24. Cabre P, Olindo S, Marignier R, Jeannin S, Merle H, Smadja D, Aegis of French National Observatory of Multiple Sclerosis (2013) Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study. J Neurol Neurosurg Psychiatry 84:511–516. doi:10.1136/jnnp-2012-303121
25. Kim S-H, Huh S-Y, Lee SJ, Joung A, Kim HJ (2013) A 5-year follow-up of rituximab treatment in patients with neuromyelitis optica spectrum disorder. JAMA Neurol 70:1110–1117. doi:10.1001/jamaneurol.2013.3071
26. Huh S-Y, Kim S-H, Hyun J-W, Joung A-R, Park MS, Kim B-J, Kim HJ (2014) Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder. JAMA Neurol 71:1372–1378. doi:10.1001/jamaneurol.2014.2057
27. Mealy MA, Wingerchuk DM, Palace J, Greenberg BM, Levy M (2014) Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy. JAMA Neurol 71:324–330. doi:10.1001/jamaneurol.2013.5699
28. Bradl M, Misu T, Takahashi T, Watanabe M, Mader S, Reindl M, Adzemovic M, Bauer J, Berger T, Fujihara K, Itoyama Y, Lassmann H (2009) Neuromyelitis optica: pathogenicity of patient immunoglobulin in vivo. Ann Neurol 66:630–643. doi:10.1002/ana.21837
29. Mitsdoerffer M, Kuchroo V, Korn T (2013) Immunology of neuromyelitis optica: a T cell-B cell collaboration. Ann N Y Acad Sci 1283:57–66. doi:10.1111/nyas.12118
30. Varrin-Doyer M, Spencer CM, Schulze-Topphoff U, Nelson PA, Stroud RM, Cree BAC, Zamvil SS (2012) Aquaporin 4-specific T cells in neuromyelitis optica exhibit a Th17 bias and recognize Clostridium ABC transporter. Ann Neurol 72:53–64. doi:10.1002/ana.23651
31. Uzawa A, Mori M, Ito M, Uchida T, Hayakawa S, Masuda S, Kuwabara S (2009) Markedly increased CSF interleukin-6 levels in neuromyelitis optica, but not in multiple sclerosis. J Neurol 256:2082–2084. doi:10.1007/s00415-009-5274-4
32. Jarius S, Wildemann B (2013) Aquaporin-4 antibodies (NMO-IgG) as a serological marker of neuromyelitis optica: a critical review of the literature. Brain Pathol Zurich Switz 23:661–683. doi:10.1111/bpa.12084
33. Kleiter I, Gold R (2015) Present and future therapies in neuromyelitis optica spectrum disorders. Neurotherapeutics. doi:10.1007/s13311-015-0400-8
34. Comi G, Filippi M, Wolinsky JS (2001) European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging–measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 49:290–297